Thomas Hecht to Chair Orion Biotechnology’s Board of Directors

OTTAWA, Ontario, November 12, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd. today announced that Dr. Thomas Hecht has been appointed Chairman of its Board of Directors. Dr. Hecht brings extensive expertise in leading value creation processes for stakeholders across the full value chain as well as deal-making with large pharmaceutical and biotechnology companies. In his new … Read moreThomas Hecht to Chair Orion Biotechnology’s Board of Directors

OB-002 Significantly Reduces Bone Metastasis in a Murine Model of Breast Cancer

OTTAWA, Ontario, October 31, 2019 (Newswire.com) – Orion Biotechnology Canada, Ltd. today announced that OB-002 was able to significantly reduce bone metastasis in a murine model of breast cancer. The study was conducted in collaboration with ProQinase (Heidelberg, Germany; https://www.proqinase.com/). Female BALB/c mice received orthotopic implantation of 4T1-M3_Luc cells into the mammary fat pad. The 4T1 breast … Read moreOB-002 Significantly Reduces Bone Metastasis in a Murine Model of Breast Cancer

Sir Gregory Winter FRS to Chair Orion Biotechnology’s Scientific Advisory Board

OTTAWA, Canada, August 6, 2019 (Newswire.com) – ​​Orion Biotechnology Canada Ltd. today announced that Sir Gregory Winter FRS has agreed to chair the Orion Biotechnology Scientific Advisory Board (SAB). Sir Gregory Winter FRS is a molecular biologist best known for his work on protein engineering and developing technologies to make therapeutic monoclonal antibodies (mAbs). Winter … Read moreSir Gregory Winter FRS to Chair Orion Biotechnology’s Scientific Advisory Board

Novel Drug Being Developed for Cancer Indications and HIV Prevention Demonstrates Best-in-Class Potency

OTTAWA, Ontario, July 23, 2019 (Newswire.com) – ​​Orion Biotechnology Canada Ltd. today announced that In vitro potency assessment of their lead compound, OB-002, has demonstrated that the chemokine analogue is more potent than other CCR5 antagonists in development for HIV prevention and cancer indications. Inhibitory potency of OB-002 was compared with maraviroc (Selzentry® or Celsentri®), … Read moreNovel Drug Being Developed for Cancer Indications and HIV Prevention Demonstrates Best-in-Class Potency

Orion Biotechnology’s CCR5 Blocker OB-002 Shows Strong Efficacy in a New Preclinical Model of Multiple Sclerosis

OTTAWA, Ontario, July 2, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd., today announced the publication of preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in a murine model of multiple sclerosis in Science Translation Medicine [1]. Viral infection early in life is a key element in determining the risk of subsequent development of multiple sclerosis … Read moreOrion Biotechnology’s CCR5 Blocker OB-002 Shows Strong Efficacy in a New Preclinical Model of Multiple Sclerosis

Orion Biotechnology Reports Additional Positive Preclinical Data for OB-002 in the Treatment of Colorectal Cancer

OTTAWA, Ontario, June 20, 2019 (Newswire.com) – ​Orion Biotechnology Canada Ltd., today announced new preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Seven days after inoculation, the mice were randomized to receive intraperitoneal treatment with OB-002, a murine anti-PD-1 antibody, … Read moreOrion Biotechnology Reports Additional Positive Preclinical Data for OB-002 in the Treatment of Colorectal Cancer

Orion Biotechnology Announces Receipt of Pre-IND Guidance From the United States FDA on the Further Development of OB-002O as a Potential Treatment for Solid Tumors

OTTAWA, Ontario, June 10, 2019 /PRNewswire/ — Orion Biotechnology Canada Ltd., today announced that it has received feedback from the Food and Drug Administration (FDA) on a Pre-Investigational New Drug (PIND) application which was submitted in March 2019. The PIND was focused on the development of OB-002O as an agent for the treatment of solid … Read moreOrion Biotechnology Announces Receipt of Pre-IND Guidance From the United States FDA on the Further Development of OB-002O as a Potential Treatment for Solid Tumors

Orion Biotechnology’s Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

OTTAWA, Ontario, May 30, 2019 (Newswire.com) – ​Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced their Chief Medical Officer, Ian McGowan MD Ph.D. FRCP, will be presenting at the ASCO meeting which is being held in Chicago (May 31st to June 3, 2019; https://meetings.asco.org/am/attend-meeting). His talk will be in the Gastrointestinal … Read moreOrion Biotechnology’s Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

The National Centre for Research and Development Awards Orion Biotechnology With a Grant to Progress Development of a Treatment for Advanced Colorectal Cancer

OTTAWA, Ontario, April 16, 2019 (Newswire.com) – ​Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary Orion Biotechnology Polska Sp. z.o.o. was awarded a grant of just under two million U.S. dollars by the Polish National Centre for Research and Development (NCBR). The grant will help co-fund a … Read moreThe National Centre for Research and Development Awards Orion Biotechnology With a Grant to Progress Development of a Treatment for Advanced Colorectal Cancer

Orion Biotechnology to Announce Novel Potency Data

OTTAWA, Ontario, March 28, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd., today announced that it will be presenting data on the potency of OB-002, their CCR5 antagonist currently in development for HIV prevention and oncology indications, at the 10th IAS HIV Science Meeting that will be held in Mexico City in July 2019. OB-002 is … Read moreOrion Biotechnology to Announce Novel Potency Data

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com